Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.68 |
| ▸ | PIK3R1 | P27986 | 10/20 | 0.68 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17234907 | 1.00 | PIK3CD (0.68) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL16119396 | 1.00 | PIK3CD (0.68) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17234898 | 0.93 | PIK3CD (0.70) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17234870 | 0.93 | PIK3CD (0.70) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17235080 | 0.93 | PIK3CD (0.70) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17235478 | 0.93 | PIK3CD (0.64) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17235165 | 0.93 | PIK3CD (0.64) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17235215 | 0.93 | PIK3CD (0.64) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17234900 | 0.91 | PIK3CD (0.72) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL17234862 | 0.91 | PIK3CD (0.72) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015168079-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS PI3K INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |